VerifyMe, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VerifyMe, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.40M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $24.21M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $25.31M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $19.58M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $867.0K | Mar 28, 2023 |
| FY2021 | Dec 30, 2021 | $867.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2020 | $343.0K | Mar 25, 2021 |
| FY2021 | Dec 30, 2020 | $343.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $245.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $74.9K | Mar 9, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2016 | $37.1K | Apr 17, 2018 |
| FY2016 | Dec 31, 2015 | $217.3K | Apr 12, 2017 |
| FY2015 | Dec 31, 2014 | $124.6K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $3.1K | Apr 16, 2015 |
| FY2013 | Dec 31, 2012 | $17.0K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $8.9K | May 13, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.32M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.66M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.03M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $6.49M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $599.0K | Mar 28, 2023 |
| FY2021 | Dec 30, 2021 | $599.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2020 | $281.0K | Mar 25, 2021 |
| FY2021 | Dec 30, 2020 | $281.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $200.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $46.1K | Mar 9, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.91M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.82M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.39M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($14.40M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.61M | Mar 28, 2023 |
| FY2021 | Dec 30, 2021 | $3.61M | Mar 14, 2022 |
| FY2021 | Dec 31, 2020 | ($5.90M) | Mar 14, 2022 |
| FY2021 | Dec 30, 2020 | ($5.90M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($2.51M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.93M) | Mar 9, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.07M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.39M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.33M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($3.75M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($4.83M) | Mar 28, 2023 |
| FY2021 | Dec 30, 2021 | ($4.83M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2020 | ($3.57M) | Mar 25, 2021 |
| FY2021 | Dec 30, 2020 | ($3.57M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($2.43M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.60M) | Mar 9, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $70.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $107.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $89.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $51.0K | Mar 28, 2023 |
| FY2021 | Dec 30, 2021 | $51.0K | Mar 14, 2022 |
| FY2021 | Dec 31, 2020 | $19.0K | Mar 14, 2022 |
| FY2021 | Dec 30, 2020 | $19.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $5.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $187.7K | Mar 9, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $603.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $871.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $244.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($2.55M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($3.25M) | Mar 28, 2023 |
| FY2020 | Dec 31, 2020 | ($2.28M) | Mar 25, 2021 |
| FY2021 | Dec 30, 2020 | ($2.28M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($1.58M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.38M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($935.9K) | Apr 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $27.0K | Mar 12, 2025 |
| FY2022 | Dec 31, 2021 | $12.0K | Mar 28, 2023 |
| FY2016 | Dec 31, 2015 | $2.4K | Apr 12, 2017 |
| FY2014 | Dec 31, 2013 | $10.6K | Apr 16, 2015 |
| FY2013 | Dec 31, 2012 | $2.4K | Mar 31, 2014 |
| FY2011 | Dec 31, 2011 | ($35.7K) | Jul 13, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $16.07M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $20.71M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $20.75M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $21.69M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $8.77M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $943.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.05M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $903.2K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $281.1K | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.03M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.85M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.17M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $7.17M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $521.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $455.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.01M | Mar 25, 2021 |
| FY2015 | Dec 31, 2015 | $2.51M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $12.69M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $7.81M | Apr 16, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.99M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.21M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $12.53M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $13.59M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $21.17M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $8.32M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($67.0K) | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $1.57M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($192.5K) | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | ($1.28M) | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.93M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.99M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.38M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $3.99M | Mar 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($90.58M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($85.67M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($81.85M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($78.46M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($64.06M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($67.67M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($61.77M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($59.26M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($56.33M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($41.64M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.82M | Mar 12, 2025 |
| FY2024 | Dec 31, 2023 | $3.03M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $3.35M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.42M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $7.94M | Mar 14, 2022 |
| FY2021 | Dec 30, 2020 | $7.94M | Mar 14, 2022 |
| FY2021 | Dec 31, 2019 | $253.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $1.67M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $693.0K | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $22.6K | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $875.0K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $1.40M | Mar 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 30, 2021 | 0 | Mar 14, 2022 |
| FY2021 | Dec 31, 2020 | (1) | Mar 14, 2022 |
| FY2021 | Dec 30, 2020 | (1) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 30, 2021 | 0 | Mar 14, 2022 |
| FY2021 | Dec 31, 2020 | (1) | Mar 14, 2022 |
| FY2021 | Dec 30, 2020 | (1) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 9, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.07M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 10.54M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 10.12M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 8.95M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 7.20M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 5.60M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 2.23M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 102.20M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 53.52M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 8.33M | Apr 17, 2018 |